Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

NCT02305381 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02305381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02305381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
December 1, 2014
Completion date
November 21, 2015
Enrollment
397 (actual)
Sites
99

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2